In the Swedish BioFINDER‐2 longitudinal cohort, higher baseline levels of CSF Axl and MerTK, in nondemented individuals at risk for AD (based on positive amyloid or tau imagery), predicted future slower tau accumulation and cognitive decline.22 Here, MAPT is linked to Alzheimer disease.